NUVB Latest Headlines

NUVB highlights nearly 50-month median response as FDA updates IBTROZI label ahead of schedule

Market Chameleon (Fri, 18-Sep 11:41 AM)

NUVB Wins FDA Label Update for IBTROZI Highlighting 49.70-Month Median Response Duration

Market Chameleon (Thu, 17-Sep 7:54 AM)

FDA Fast Track Designation for Safusidenib Highlights Nuvation Bio’s Breakthrough in IDH1-Mutant Glioma

Market Chameleon (Thu, 20-Aug 8:59 AM)

Nuvation Bio’s Second Quarter 2026: IBTROZI Prescriptions Show Strong Growth, Financials Reflect Solid Market Position

Market Chameleon (Thu, 6-Aug 7:48 AM)

Positive Phase 2 Data Drives Expansion of Nuvation Bio’s Safusidenib Program into Two New Glioma Studies

Market Chameleon (Mon, 20-Jul 11:44 AM)

Nuvation Bio Raises $287.5 Million with Full Greenshoe Option Exercise—Capped Call Pricing Reveals Aggressive Upside

Market Chameleon (Tue, 7-Jul 9:40 AM)

Nuvation Bio Proposes $200 Million Convertible Senior Notes Offering to Streamline Debt and Fund Growth Initiatives

Market Chameleon (Thu, 25-Jun 7:29 AM)